A randomized, open-label, multicenter, comparative study of therapeutic efficacy, safety and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb in the treatment of acute non-bacterial tonsillitis in children aged 6 to 18 years

Popovych, Vasyl I.; Koshel, I V; Malofiichuk, Alexander; Pyletska, Lyubov; Semeniuk, A V; Филиппова, О. В.; Orlovska, Ruslana

doi:10.1016/j.amjoto.2018.10.012

Cited by 33 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite its traditional value, there is an obvious scarcity of studies regarding its benefits in the pediatric population. We have identified only one randomized, multicenter study evaluating the therapeutic efficacy of a herbal extract containing walnut leaves (in mixture with other six plants) in the treatment of acute non-bacterial tonsillitis in children aged 6 to 18 years [148]. The conclusion of the study was that the extract is safe and effective.…”

Section: Comparison Of Relative Therapeutic Versatility Of Top Medicimentioning

confidence: 99%

Historical ethnobotanical review of medicinal plants used to treat children diseases in Romania (1860s–1970s)

Petran

Dragoș

Gîlcă

2020

J Ethnobiology Ethnomedicine

View full text Add to dashboard Cite

Background: Romanian ethnopediatrics has a long history of medicinal plant use. The main objective of the present review was to identify, collect, systematize, and prioritize the available bibliographical data related to medicinal plants traditionally used to treat various pediatric diseases in Romania during the 1860s-1970s. Methods: Information was mainly obtained by manual systematic search in various relevant historical works focused on the traditional use of medicinal plants in Romania (1860s-1970s), found in the Archives of Romanian Academy Library and National Romanian Library. Results: A total of 153 medicinal plants belonging to 52 families were identified as having ethnopediatric significance. The plant traditional indications, targeted body systems, parts used, and way of administration were provided. We have also proposed one index (expressed as percentage) in order to assess the ethnopediatric applicability area of species: ethnopediatric relative therapeutic versatility (ERTV), which was calculated on the basis of the number of distinct uses mentioned for a species. The species identified to have the highest ERTV scores were Dryopteris filix-mas (100%), Gratiola officinalis (85.71%), Allium sativum (71.42%), Eryngium planum (71.42%), Juglans regia (71.42%), Matricaria chamomilla (71.42%), Plantago major (71.42%). Conclusions: The present study exposed for the first time to the international scientific community important ethnopediatric information contained in several local Romanian bibliographical resources that could guide the local and international researchers towards new directions of plant valorization.

show abstract

Section: Comparison Of Relative Therapeutic Versatility Of Top Medicimentioning

confidence: 99%

Historical ethnobotanical review of medicinal plants used to treat children diseases in Romania (1860s–1970s)

Petran

Dragoș

Gîlcă

2020

J Ethnobiology Ethnomedicine

View full text Add to dashboard Cite

show abstract

“…Supplemental use of a phytoneering medicinal product BNO 1030 for treatment of acute tonsillitis has been shown to promote considerable decrease of tonsillitis clinical symptoms, improved assessment of patients' general condition and their quality of life, decrease of the rate of use of antipyretics and overall treatment duration without any adverse events. Prospects for further studies consist in investigation of anti-relapse efficacy of the drug in patients with recurrent tonsillitis [15]. Acute respiratory viral infections (ARVI) in children are common and often recurrent.…”

Section: Sinupret® Extract: a History Of Success (Prof Claus Bachertmentioning

confidence: 99%

Review of the Phytoneering Research & Experience Summit (PRES) 2019 “building bridges between nature’s healing potential and evidence-based medicine - 20 years of phytoneering”

et al. 2020

View full text Add to dashboard Cite

This brief communication summarizes the key highlights presented at the 2019 Phytoneering Research and Experience Summit held at the Palma Convention Centre and the educational finca Sa Canova (Majorca, Spain) from the 25th to the 27th of July 2019. More than 100 professionals from academia, industry and public services took part. The scientific programme included three dedicated symposium sessions and a moderated poster session. In total, 13 oral communications and 23 posters were presented. The invite-only conference, entitled: "Phytoneering Research & Experience Summit (PRES) 2019-Building bridges between nature's healing potential and evidence-based medicine-20 years of phytoneering", had participants from 20 different nations, reflecting the international character of the event. This participant group included researchers as well as clinicians with different fields of interest, e.g. gynaecology, urology, respiratory diseases and paediatrics. They all share an interest in evidence-based phytotherapy and phytoneering, which is the combination of ancient knowledge about medicinal plants and state-of-the-art technology to produce evidence-based herbal medicine. This approach offers solutions to reduce the growing number of unnecessarily prescribed antibiotics in the abovementioned areas, with the aim of preventing further progression of antibiotic resistance. The conference was sponsored by Bionorica® SE.

show abstract

“…The copyright holder for this this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.10.21253255 doi: medRxiv preprint inflammatory and immunomodulatory effects [25,26,27]; indications for use are "treatment of upper respiratory tract diseases (tonsillitis, pharyngitis, laryngitis) and the prevention of complications in viral respiratory infections". Clinical studies in children have shown that the additional use of the phytoneering drug BNO 1030 (Imupret®) for the treatment of acute tonsillitis significantly reduces the clinical symptoms of tonsillitis, improves the assessment of the patients' general well-being and quality of life, reduces the use of NSAIDs and the overall duration of treatment with no side effects [28,29]. However, in the scientific literature, there are no reports on efficacy studies of Imupret® with delayed antibiotic prescription in patients with acute rhinosinusitis which comply with GCP standards.…”

Section: Introductionmentioning

confidence: 99%

Multicenter, Randomized, Open-Label, Comparative Study of Therapeutic Efficacy, Safety and Tolerability of BNO 1030 application in the technology of delayed prescription of antibiotics in patients with severe acute tonsillitis

Popovych

Koshel²,

Om³

et al. 2021

Preprint

View full text Add to dashboard Cite

Acute bacterial tonsillitis occurs from 20 to 30 % of immunocompetent children; however, the frequency of antibacterial drug prescriptions reaches up to 90 %. Delayed antibiotic prescription is recommended by current guidelines. The study objective was to determine the efficacy of phytoneering extract BNO 1030 in the technology of delayed antibiotic prescription in patients with severe acute tonsillitis. Methods. In the multicenter, randomized, open label, comparative study, 182 out of 200 randomized children with acute tonsillitis aged from 6 to 12 years completed the study. Evaluation criteria: a reduced severity of sore throat when swallowing and at rest, throat irritation at rest, hyperemia of the tonsils assessed by a physician according to a 4 point scale at each visit compared to Visit 1, dynamics of self assessment of general well-being, the intensity of sore throat and difficulty swallowing according to a 10 point visual analog scale, frequency of antibiotic prescriptions, therapeutic benefit from BNO 1030 in days. Results. The use of phytotherapeutic medicinal product BNO 1030 in addition to the standard symptomatic treatment of severe acute tonsillitis provides a clinically significant, adequate reduction in the symptom severity assessed by a physician at V2 (p < 0.005). There are significant differences in the patient self assessment of the symptoms from treatment Day 2 (p < 0.005). This allows to significantly reduce the duration of systemic antipyretic administration (p < 0.005). In the first days of treatment, when a decision on the delay of antibiotic prescription is made, a therapeutic benefit in two days in patients of the treatment group was observed compared to the control group. The use of BNO 1030 in patients with severe acute tonsillitis significantly reduces, by 43.7 % or 2.3 times, the need for prescribing antibiotic therapy as part of the technology of delayed antibiotic prescription (p < 0.005). During treatment, no side effects and complications of the disease were recorded. Conclusion. BNO 1030 is a safe and effective medicinal product for the treatment of severe acute tonsillitis in children aged from 6 to 12 years. It provides a significant therapeutic benefit when administered in addition to standard symptomatic therapy and reduces the irrational antibiotic prescription.

show abstract

Cited by 33 publications

References 10 publications

Historical ethnobotanical review of medicinal plants used to treat children diseases in Romania (1860s–1970s)

Historical ethnobotanical review of medicinal plants used to treat children diseases in Romania (1860s–1970s)

Review of the Phytoneering Research & Experience Summit (PRES) 2019 “building bridges between nature’s healing potential and evidence-based medicine - 20 years of phytoneering”

Multicenter, Randomized, Open-Label, Comparative Study of Therapeutic Efficacy, Safety and Tolerability of BNO 1030 application in the technology of delayed prescription of antibiotics in patients with severe acute tonsillitis

Contact Info

Product

Resources

About